Durata Therapeutics, which is developing a Phase 3 antibiotic candidate for acute skin infections, raised $68 million by offering 7.5 million shares at $9, below the range of $11 to $13. Because Durata had planned to offer only 6.3 million shares, the proceeds...read more
Durata Therapeutics, a acquired rights from Pfizer to a Phase 3 candidate for the treatment of skin infections, announced terms for its IPO on Monday. The Morristown, NJ-based company plans to raise $75 million by offering 6.3 million shares at a price range of...read more
Durata Therapeutics, which acquired rights from Pfizer to a Phase 3 candidate for the treatment of skin infections, filed on Thursday with the SEC to raise up to $86 million in an initial public offering. The Phase 3 trials for dalbavancin, which is administered...read more
Durata Therapeutics prices IPO at $9, below the range
Durata Therapeutics, which is developing a Phase 3 antibiotic candidate for acute skin infections, raised $68 million by offering 7.5 million shares at $9, below the range of $11 to $13. Because Durata had planned to offer only 6.3 million shares, the proceeds...read more
5 US IPOs planned for the week of Jul 16
The following IPOs are expected to price this week:
Durata Therapeutics (DRTX), which is developing Phase 3 antibiotic candidate for acute skin infections, plans to...read more
Durata Therapeutics sets terms for $75 million US IPO
Durata Therapeutics, a acquired rights from Pfizer to a Phase 3 candidate for the treatment of skin infections, announced terms for its IPO on Monday. The Morristown, NJ-based company plans to raise $75 million by offering 6.3 million shares at a price range of...read more
Biotech Durata Therapeutics files for $86 million US IPO
Durata Therapeutics, which acquired rights from Pfizer to a Phase 3 candidate for the treatment of skin infections, filed on Thursday with the SEC to raise up to $86 million in an initial public offering. The Phase 3 trials for dalbavancin, which is administered...read more